Solid Tumor Testing in Japan Trends and Forecast
The future of the solid tumor testing market in Japan looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1641.7 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The solid tumor testing market in Japan is also forecasted to witness strong growth over the forecast period. The major drivers for this market are an increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.
• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
Emerging Trends in the Solid Tumor Testing Market in Japan
In Japan, the market for testing solid tumors is continually on the rise due to enhancements in rational medicine and the application of advanced artificial intelligence in oncology. Because Japan is renowned for its healthcare system, the country continues to adopt new methods for the detection, treatment, and monitoring of solid tumors. All of these methods are changing the face of cancer care in the nation, with a focus on the exceptional precision required for detection and treatment. Below are five key emerging trends in the Japanese market for solid tumor testing.
• Adoption of Liquid Biopsy for Early Detection: One of the biggest changes happening now in Japan is liquid biopsy, which is revolutionizing early cancer detection by identifying tumor RNA or DNA in blood samples. Liquid biopsy allows for a less invasive method of obtaining results, which is expected to have a better outcome than conventional tissue biopsies. With the continuous rise of liquid biopsies, among other methods, the detection of solid tumors in primary stages is becoming more common, especially in lung and colorectal cancers. For obvious reasons, this particular trend helps achieve better outcomes for patients by making it unnecessary to perform highly intrusive procedures.
• Use of AI in Diagnostic Imaging Practice: In Japan, AI-assisted diagnostic imaging for solid tumors is increasingly becoming a valuable resource for detecting and evaluating tumors. By using machine learning techniques, AI systems are able to pick up subtle alterations in the size and position of tumors that human clinicians may overlook. This makes early diagnosis more precise and effective, which means treatment decisions made are more favorable. Using AI in the everyday routine tasks of cancer management is improving workflow and diagnostic precision, which in turn improves patient care and facilitates treatment planning.
• Increased Adoption of Genomic Profiling and Precision Medicine: In Japan, the use of genomic profiling to customize treatment modalities for cancer patients is on the rise. Oncologists can derive targeted therapy from genetic alterations of solid tumors, which is more potent and has minimal side effects. Such targeted treatments are now being embraced for lung cancer, breast cancer, and colorectal cancer. An increase in the availability of genomic profiling is likely to improve the practice of oncology by advancing precision medicine and enhancing the quality of care for patients needing specific treatment interventions.
• Focus on Early Detection Screening Programs: Japan has been concentrating on improving its cancer detection through its screening programs. Recent innovations such as liquid biopsy, genetic sequencing, and AI image analysis are being used for early cancer detection at a stage that is more manageable. These advancements in prevention are likely to raise the demand for solid tumor testing in Japan, as doing so fully optimizes chances of survival and significantly lowers healthcare costs. Additionally, there is more public and government support for these initiatives.
• Development of Minimally Invasive Diagnostic Tools: Japan appears to be increasingly focused on developing new technologies for minimally invasive solid tumor diagnosis. Liquid biopsy, microendoscopy, and other non-invasive imaging techniques that do not rely on surgical procedures are becoming more and more popular. Such technologies not only save time and lessen patient recovery discomfort but also reduce total healthcare expenditures associated with hospital admissions and surgeries. This trajectory, if sustained, would continue to foster growth in the solid tumor testing market.
With the implementation of liquid biopsy techniques, the fusion of AI with medical imaging diagnostics, and the onset of personalized medicine and early detection systems, cancer care is changing. The aforementioned innovations are increasing both the detection and treatment of cancer, as well as improving overall health outcomes for patients. This is significant, and as ongoing developments reveal, Japan is leading the charge in precision oncology, something that will change their healthcare system and solid tumor testing market. Revisions in the solid tumor testing market suggest that Japan isn’t straying far from developing technologies.
Recent Developments in the Solid Tumor Testing Market in Japan
Japan’s market for solid tumor testing has experienced a boom in diagnostic technology, personalized medicine, and even campaign initiatives focused on early detection. These increases are guiding advancements in cancer detection and treatment in the country, making them more sophisticated, timely, and non-invasive. There is certainly more to explore with these expanded capabilities, as the country strives for more efficient cancer identification and enhanced patient care. The following are five notable developments in Japan’s solid tumor testing market.
• Increase in the Adoption of Liquid Biopsies: In Japan, liquid biopsy is gaining popularity because it can identify cancer-related genetic materials in blood samples. Unlike traditional biopsies, liquid biopsies require no invasive procedures and provide results much more quickly. This technique is highly beneficial for assessing treatment response, monitoring cancer relapses, and diagnosing the disease at earlier stages. As the accuracy and availability of liquid biopsy technology increase, it is projected that liquid biopsies will become integral in solid tumor testing in Japan, leading to advanced cancer detection and treatment in the country.
• Application of AI Technology in Cancer Diagnosis: In Japan, the application of artificial intelligence (AI) in oncology is on the rise. Medical imaging data, specifically CT and MRI scans, are analyzed through specific algorithms to improve solid tumor detection and tracking. These systems can detect patterns in scans that are difficult for humans to notice, leading to earlier detection of most tumors. The incorporation of AI into the imaging diagnostic workflow is improving the accuracy of cancer screening, enabling clinicians to detect tumors much earlier and devise more effective treatment plans.
• Personalized Medicine in Cancer Treatment: Personalized medicine is on the rise in cancer treatment in Japan. Oncologists can sequence the genome of the tumor and find a cure for the patient’s cancer with the help of genomic profiling. This approach is especially useful in the treatment of solid tumors, as it enables the provision of more precise therapies that mitigate adverse effects. If Japan continues with the current trend of progress in genomic profiling, the country’s cancer patients will benefit from a sophisticated healthcare system that boosts life expectancy and quality of life.
• New Approaches to Biopsy: To improve detection and monitoring of solid tumors in Japan, non-invasive testing methods are being developed. Liquid biopsy, as well as other non-invasive imaging methods, is becoming more popular as they are effective at identifying the presence of solid tumors with minimal invasion and at much quicker rates. These technological breakthroughs will certainly help change the perception of cancer struggles by focusing on less painful and more accurate methods. Non-invasive methods are set to become the future of solid tumor diagnosis and, as a result, will improve the patient experience and change how cancer markers are evaluated.
• Supporting New Initiatives in Cancer Detection Programs by the Government: Cancer detection is receiving close attention from the Japanese government through new screening programs. Government-backed initiatives seek to advance the detection of solid tumors using advanced methods such as genetic testing and AI-powered imaging. The goal is to broaden the scope of early-stage detection in Japan, where solid tumors are tested. This will increase life expectancy and lessen the impacts and expenses of cancer on healthcare. As government support expands, cancer care programs will become more elaborate and easier to access nationwide.
Consumers’ interest in Japan’s solid tumor testing market makes it evident that the emergence of liquid biopsy, AI technology in diagnostics, precision medicine, non-invasive procedures, and government-endorsed cancer programs will support the creation of a more robust cancer care system. These trends should improve the accuracy, speed, and availability of solid tumor testing, transforming patient outcomes. Adoption of these changes is already taking place in Japan, so its innovations will drive positive growth in Japan’s solid tumor testing market.
Strategic Growth Opportunities for Solid Tumor Testing Market in Japan
Rapid advancements in diagnostic technologies, evolving healthcare policies, and greater awareness of early cancer detection have fueled the growth of solid tumor testing in Japan. The country is seeking newer ways to identify cancer cases more efficiently and improve patient outcomes, and many strategic growth opportunities across key applications are helping achieve the desired result. These advancements are set to transform the market for solid tumor testing by offering innovative solutions to improve accuracy, reduce invasiveness, and tailor treatments to personal needs.
• Adoption of Liquid Biopsy for Early Detection: Liquid biopsy has the potential to become the leading method of cancer identification, complementing traditional approaches. Traditional methods, which include complex and invasive techniques, are not only painful but also time-consuming. Liquid biopsy allows for the collection of blood samples and analysis of tumor DNA or RNA without the need for surgery. It is particularly beneficial for lung and colorectal cancer detection. Japan’s solid tumor testing market is set to expand steadily as the technology improves cancer screening results and monitoring processes become more efficient.
• Integration of AI in Diagnostic Imaging: In Japan, artificial intelligence (AI) is increasingly being used to detect and monitor solid tumors. The development of AI technologies, especially in machine learning, makes it possible to analyze complex imaging datasets, such as CT and MRI scans, to detect changes that are almost invisible to human radiologists. AI-assisted diagnosis improves the accuracy and speed of diagnoses, enabling better treatment for tumors. The incorporation of AI into everyday diagnostic procedures is increasing patients’ access to healthcare and improving the overall efficiency of cancer treatment in Japan.
• Genomic Profiling for Personalized Medicine: A patient’s genomic profile contains information necessary for designing effective and non-toxic targeted therapies. In Japan, the adoption of genomic profiling among cancer patients, especially for solid tumors like lung and breast cancer, is expanding. The growth potential in this area allows oncologists to prescribe the best treatment combinations that will yield optimal results for specific patients. Personalized medicine will change the face of cancer care, making it the foremost growth area for the solid tumor testing market in Japan by providing novel and targeted therapies.
• Advanced Diagnostic Tools that are Less Invasive: Advanced robotic imaging technology and micro-endoscopy are examples of advanced diagnostic tools that are increasingly being used in Japan for solid tumor detection and monitoring. These methods limit the extent of surgical procedures required, enabling quicker recovery and reduced discomfort for patients. Other non-invasive techniques, such as liquid biopsy and advanced imaging methods, allow for tumor detection with great efficiency without the need for surgery. As acceptance of these technologies grows, the need for less invasive diagnostic procedures will increase, boosting the growth of solid tumor diagnostics in Japan and improving the patient’s experience and the effectiveness of healthcare.
• Screening Initiatives by the Government: The government of Japan is intensifying efforts on cancer prevention and early diagnosis by endorsing programs that utilize genetic, AI-powered imaging, and liquid biopsy technologies within national screening programs. These programs aim to diagnose cancer at earlier and more treatable stages to improve life expectancy and lower healthcare costs. With government support, these new technologies become more accessible to the population, increasing competition in the solid tumor market. The public health system addressing these issues will ensure further growth in the solid tumor testing market in Japan.
Liquid biopsy, AI development, genomic profiling, advanced diagnostic tools, and government screening programs are key growth opportunities poised to greatly influence Japan’s solid tumor testing market. With the progression of each of these segments, the market is bound to mature and increase in sophistication, leading to improved precision in diagnosis and treatment. These factors are gaining momentum globally, and Japan’s ecosystem will evolve into a more comprehensive system, improving healthcare provision for patients suffering from cancer.
Solid Tumor Testing Market in Japan Driver and Challenges
The solid tumor testing market in Japan has experienced growth due to a combination of competitive, state-of-the-art technologies, available funds, and regulation policies. Key drivers include technological innovation, increased demand for health services, and new governmental policies, which help foster the growth of the solid tumor testing market. However, there are challenges, such as stringent compliance requirements, budgetary constraints, and the availability of skilled professionals. Some drivers and challenges are self-evident about the market’s composition, while the presence of barriers that hinder growth requires careful investigation.
The factors responsible for driving the solid tumor testing market in Japan include:
• Progress in Technology Related to Diagnostic Devices: Cutting-edge technology like AI, liquid biopsy, and genomic profiling is making significant impacts on solid tumor testing in Japan. These technologies help increase the speed and accuracy of cancer detection, making the process less invasive and allowing for early diagnosis and treatment. The implementation of these advanced diagnostic tools improves treatment success rates and patient outcomes, which directly increases the demand for solid tumor testing. These trends indicate that Japan’s solid tumor testing market will continue to grow as health diagnostics become more technologically advanced, allowing the country to better manage its cancer control efforts.
• Increased Cancer Prevalence Alongside the Aging Population: With the growing number of cancer patients alongside Japan’s aging population, there is an increasing demand for more sophisticated and easier approaches to cancer detection. As Japanese citizens age, there is a higher risk of developing solid tumors, which in turn increases the need for testing services. There has been a noticeable increase in the number of cancer patients, leading to increased spending in the solid tumor testing market as patients and healthcare practitioners seek more accurate diagnostic measures. This demographic trend is a major market factor.
• Government Initiatives and Support for Cancer Care: The proactive engagement of the Japanese government in facilitating cancer screening through national programs and policies has been beneficial. The government’s support for advanced technologies like liquid biopsy and AI is helping to make cancer testing more accessible and affordable. Such policies improve health outcomes while also fostering the growth of the solid tumor testing industry, promoting innovation and adoption of new testing technologies.
• Growing Patient Demand for Personalized Medicine: The rise in the number of patients seeking specific types of treatment is greatly increasing the need for sophisticated diagnosis and treatment. A significant growth driver in Japan’s solid tumor testing market is genomic profiling, which customizes cancer therapy based on the genetics of the patient’s tumor. Personalized medicine leads to better treatments with fewer side effects, improving the quality of life for patients. The movement toward individualized care is stimulating demand for more advanced diagnostic tools, driving market growth.
• Enhanced Healthcare Infrastructure and Market Expansion: Japan’s strong and well-developed healthcare system is a leading factor influencing the growth of the solid tumor testing market. The country’s sophisticated healthcare system allows for the use of the latest diagnostic techniques, such as liquid biopsies and imaging through artificial intelligence. The increasing accessibility of these advanced methods, especially in rural and underserved regions, is boosting market growth and improving patient outcomes nationwide.
Challenges in the solid tumor testing market in Japan are:
• Barriers Associated with Regulations and Reimbursements: Japan’s solid tumor testing market is highly competitive, but the approval of new diagnostic methods poses a considerable regulatory challenge. New technologies must undergo rigorous checks for safety and effectiveness before they can be used in clinical practice, leading to hesitation among decision-makers. There is also concern regarding inadequate reimbursement policies for new technologies. These barriers are a persistent concern for patients seeking timely care. The efficient utilization of these new tools is hindered by delays in the approval process and uncertainty surrounding reimbursement policies.
• High Costs of Liquid Biopsies and Genomic Profiling: Liquid biopsies and genomic profiling represent the pinnacle of modern medicine, but their high costs serve as a barrier to large-scale integration. The expenses of these diagnostic methods may deter healthcare providers from using them extensively, particularly in public healthcare systems. Although the prices of these technologies are expected to decrease over time, the current high costs present a formidable barrier to market expansion, ultimately putting patients at risk.
• The Complexity of Test Interpretation: Japan’s radiology, genomics, and AI workforce skills gap presents challenges for the solid tumor testing market, which is highly dependent on advanced diagnostic technologies. These technologies are only as effective as the people interpreting the results, and without a properly trained workforce, advanced diagnostic technologies will remain underutilized.
In Japan, the market opportunities for solid tumor testing are influenced by various drivers and challenges. The region’s advancement in technology, aging population, government support, growing demand for personalized medicine, and strong healthcare infrastructure are all contributing to the market’s growth. However, regulatory complexities, high costs, and lack of expertise are significant challenges. Despite these obstacles, the growth opportunities remain strong, as Japan continues to invest in innovative diagnostic technologies and work to eliminate the barriers that restrict their use.
List of Solid Tumor Testing Market in Japan Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, solid tumor testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Solid Tumor Testing Market in Japan by Segment
The study includes a forecast for the solid tumor testing market in Japan by type, application, and end use.
Solid Tumor Testing Market in Japan by Type [Analysis by Value from 2019 to 2031]:
• Genetic Testing
• Conventional Testing
Solid Tumor Testing Market in Japan by Application [Analysis by Value from 2019 to 2031]:
• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others
Solid Tumor Testing Market in Japan by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions
Features of the Solid Tumor Testing Market in Japan
Market Size Estimates: Solid tumor testing in Japan market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Solid tumor testing in Japan market size by type, application, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, application, and end use for the solid tumor testing in Japan.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing in Japan.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the solid tumor testing market in Japan?
Answer: The major drivers for this market are increase in the utilization of supplements and steroids and increase in unhealthy habits, such as smoking and alcohol consumption.
Q2. What are the major segments for solid tumor testing market in Japan?
Answer: The future of the solid tumor testing market in Japan looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets.
Q3. Which solid tumor testing market segment in Japan will be the largest in future?
Answer: Lucintel forecasts that melanoma is expected to witness the highest growth over the forecast period due to growing incidence of skin tumors and related conditions globally.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market in Japan by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), and end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Solid Tumor Testing Market in Japan, Solid Tumor Testing Market in Japan Size, Solid Tumor Testing Market in Japan Growth, Solid Tumor Testing Market in Japan Analysis, Solid Tumor Testing Market in Japan Report, Solid Tumor Testing Market in Japan Share, Solid Tumor Testing Market in Japan Trends, Solid Tumor Testing Market in Japan Forecast, Solid Tumor Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.